Direct renin inhibitor in the treatment of paroxysmal atrial fibrillation
https://doi.org/10.18705/1607-419X-2010-16-1-74-81
Abstract
Atrial fi brillation is the most common heart rhythm disturbance. Hypertension is a well-established risk factor for many
cases of atrial fi brillation, but its predictors are still unknown. The available treatment approaches for atrial fi brillation
management are characterized by limited effectiveness and high risk of side effects, thus encouraging researches for new
studies. Better understanding of the mechanisms leads to the development of new therapy approaches. This paper presents
the results of the study of atrial fi brillation prevention in hypertensive patients getting direct renin inhibitor.
cases of atrial fi brillation, but its predictors are still unknown. The available treatment approaches for atrial fi brillation
management are characterized by limited effectiveness and high risk of side effects, thus encouraging researches for new
studies. Better understanding of the mechanisms leads to the development of new therapy approaches. This paper presents
the results of the study of atrial fi brillation prevention in hypertensive patients getting direct renin inhibitor.
About the Authors
B. A. Tatarsky
Almazov Federal Heart, Blood and Endocrinology Centre
Russian Federation
Russian Federation
N. V. Kazyonova
Almazov Federal Heart, Blood and Endocrinology Centre
Russian Federation
Russian Federation
N. V. Serebryakov
Clinical Hospital № 226
Russian Federation
Russian Federation
References
1. Kannel W., Wolf P., Benjamin E. et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fi brillation: population-based estimates // Am. J. Cardiol. - 1998. - Vol. 82, № 8А. - P. 2N-9N.
2.
3. Benjamin E., Levy D., Vaziri S. et al. In dependent risk factors for atrial fi brillation in a population-based cohort. The Framingham Heart Study // J. Am. Med. Assoc. - 1994. - Vol. 271, № 11. - P. 840-844.
4.
5. Miller J., Zipes D. Management of the patient with cardiac arrhythmias // A textbook of cardiovascular medicine. - Philadelphia:W.B. Saunders company, 2001. - P. 731-736.
6.
7. Krahn A., Manfreda J., Tate R. et al. The natural history of atrial fi brillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study // Am. J. Med. - 1995. - Vol. 98, № 5. - P. 476-484.
8.
9. Stewart S., Hart C., Hole D. et al. A population-based study of the long-term risks associated with atrial fi brillation: 20-year followup of the Renfrew/Paisley study // Am. J. Med. - 2002. - Vol. 113, № 5. - P. 359-364.
10.
11. Futterman L.G., Lemberg L. Atrial fibrillation // Am. J. Crit. Care. - 2005. - Vol. 14, № 5. - P. 438-440.
12.
13. Zaman A., Kearney M., Schecter C. et al. Angiotensin-converting enzyme inhibitors as adjunctive therapy in patients with persistent atrial fi brillation // Am. Heart J. - 2004. - Vol. 147, № 5. - P. 823-827.
14.
15. Татарский Б.А. Использование ингибиторов АПФ при лечении пароксизмальной формы фибрилляции предсердий // Рос. кардиол. журн. - 2005. - № 5. - С. 58-62.
16.
17. Tveit A., Seljeflot I., Grundvold I., et al. Results from the CAPRAF Study, a prospective, randomized, placebo-controlled study //Int. J. Cardiol. - 2007. - Vol. 111. - P. 30-35.
18.
19. Smit M., Van Gelder I., Tomoda H. et al. the Gruppo Italiano per lo studio della sopravvive. Valsartan and recurrent atrial fi brillation //N. Engl. J. Med. - 2009. - Vol. 361, № 5. - P. 532-533.
20.
21. Atlas S. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition // J. Manag. Care Pharm. - 2007. - Vol. 13 (Suppl. B). - P. 9-20.
22.
23. Татарский Б.А., Воробьев И.В. Роль нарушений предсер- дного проведения возбуждения в генезе фибрилляции предсердий и возможности их регистрации // Вестн. аритмологии. - 2006. - Т. 41. - С. 39-46.
24.
25. Татарский Б.А., Воробьев И.В. Исследования нарушения предсердного проведения возбуждения в патогенезе фибрилляции предсердий с помощью чреспищеводной Р-сигнал усредненной нефильтрованной и фильтрованнойЭКГ // Вестн. аритмологии. - 2004. - Т. 35. - С. 77-79.
26.
27. Allessie M., Ausma J., Schotten U. Electrical, contractile and structural remodeling during atrial fi brillation // Cardiovasc. Res. - 2002. - Vol. 54, № 2. - P. 230-246.
28.
29. Yu W., Chen S., Lee S. et al. Tachycardia-induced change of atrial refractory period in humans: rate dependency and effects of antiarrhythmic drugs // Circulation. - 2006. - Vol. 97. - P. 2331-2337.
30.
31. Nakashima H., Kumagai K., Urata H. Angiotensin II antagonist prevents electrical remodeling in atrial fi brillation // Circulation. - 2000. - Vol. 101, № 22. - P. 2612-2617.
32.
33. McEwan P., Gray G., Sherry L. et al. Differential effects of angiotensin II on cardiac cell proliferation and intramyocardial perivascular fi brosis // Circulation. - 1998. - Vol. 98, № 24. - P. 2765-2773.
34.
35. Boldt A., Wetzel U., Weigl J. et al. Expression of angiotensin II receptors in human left and right atrial tissue in atrial fi brillation with and without underlying mitral valve disease // J. Am. Coll. Cardiol. - 2003. - Vol. 42, № 10. - P. 1785-1792.
36.
37. Batenburg W., Danser A. Prorenin and the (pro)renin receptor: binding kinetics, signaling and interaction with aliskiren // J. Renin Angiotensin Aldosterone Syst. - 2008. - Vol. 9, № 3. - P. 181-184.
38.
39. Danser A., Deinum J. Renin, prorenin, and the putative prorenin receptor // Hypertension. - 2005. - Vol. 46, № 5. - P. 1069-1076.
40.
41. Oliver J. Receptor mediated actions of renin and pro-renin // Kidney Int. - 2006. - Vol. 69, № 1. - P. 13-15.
42.
Review
For citations:
Tatarsky B.A., Kazyonova N.V., Serebryakov N.V. Direct renin inhibitor in the treatment of paroxysmal atrial fibrillation. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2010;16(1):74-81. (In Russ.) https://doi.org/10.18705/1607-419X-2010-16-1-74-81
Views:
890
Email this article 